Christopher Nelson - 23 Jun 2023 Form 4 Insider Report for QSAM Biosciences, Inc. (QSAM)

Role
EVP Corp Dev & General Counsel
Signature
/s/ Christopher M. Nelson
Issuer symbol
QSAM
Transactions as of
23 Jun 2023
Transactions value $
$0
Form type
4
Filing time
23 Jun 2023, 16:30:29 UTC
Previous filing
04 Jan 2023
Next filing
13 Feb 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction QSAM Common Stock Award $0 +46,365 +36.52% $0 173,317 23 Jun 2023 Direct F1
holding QSAM Series B 4,557 23 Jun 2023 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding QSAM Options to buy common stock 12,500 23 Jun 2023 Common Stock 12,500 $10 Direct F3
holding QSAM Options to buy common stock 2,875 23 Jun 2023 Common Stock 2,875 $14.4 Direct F4
holding QSAM Options to buy common stock 60 23 Jun 2023 Common Stock 60 $20 Direct
holding QSAM Options to buy common stock 255 23 Jun 2023 Common Stock 255 $20 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This award of shares is being made pursuant to the Issuer's restricted stock award agreement and is subject to a vesting schedule, such that a portion or all of this award of restricted stock may be forfeited in the future if certain milestones are not met.
F2 Represents shares of Common Stock receivable upon conversion of Series B Preferred Stock at a conversion rate of $5.42 per share, and includes accrued dividends as of 05/31/2023.
F3 The option vests annually in two equal installments beginning on 3/3/2023.
F4 The option vests semi-annually in two equal installments beginning on 2/24/2022